Frovocimab (LY 3015014; 10 mg/kg; i.v; once) causes significant PCSK9 accumulation, its duration of LDL lowering is reduced, and its clearance (CL) from serum is accelerated in mice expressing a noncleavable variant of human PCSK9[1].
Frovocimab (LY 3015014; 5 mg/kg; i.v; once) decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum[1].
| Animal Model: | Male C57BL/6NTac mice injected with vector containing the NC R215A/R218A variant[1] |
| Dosage: | 10 mg/kg |
| Administration: | i.v; once |
| Result: | Caused significant PCSK9 accumulation.
|
| Animal Model: | Cynomolgus monkeys[1] |
| Dosage: | 5 mg/kg |
| Administration: | i.v; once |
| Result: | Decreased LDL cholesterol in monkeys. |
